首页 > 最新文献

Drug and Therapeutics Bulletin最新文献

英文 中文
Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa. 一名化脓性扁桃体炎患者对塞库单抗的迟发性药物超敏反应。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2024-04-25 DOI: 10.1136/dtb.2023.249684rep
Sasank Konda, Nayha Shetty, Ben Friedman, Jesse Veenstra
{"title":"Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa.","authors":"Sasank Konda, Nayha Shetty, Ben Friedman, Jesse Veenstra","doi":"10.1136/dtb.2023.249684rep","DOIUrl":"10.1136/dtb.2023.249684rep","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"77-79"},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9752554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicines and global warming: a complex problem 药品与全球变暖：一个复杂的问题
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2024-04-09 DOI: 10.1136/dtb.2024.000003
James A Cave
The healthcare sector is responsible for 4.6% of global greenhouse gas emissions.1 Significant contributors to this carbon footprint are the biotech and pharmaceutical industries, directly from the running of these companies (sometimes called scope 1 emissions) and indirectly from purchased energy consumed (scope 2 emissions) and all other emissions indirectly associated with the companies—such as supply chains (scope 3 emissions).2 It is estimated that scope 1, 2 and 3 emissions of biotech and pharmaceutical companies accounted for 260 million tons of carbon dioxide equivalent emissions in 2021, higher than global emissions from the forestry and paper industry.2 There are particular …
医疗保健行业占全球温室气体排放量的 4.6%。2 据估计，2021 年生物技术和制药公司的范围 1、2 和 3 排放量占二氧化碳当量排放量的 2.6 亿吨，高于全球林业和造纸业的排放量。
{"title":"Medicines and global warming: a complex problem","authors":"James A Cave","doi":"10.1136/dtb.2024.000003","DOIUrl":"https://doi.org/10.1136/dtb.2024.000003","url":null,"abstract":"The healthcare sector is responsible for 4.6% of global greenhouse gas emissions.1 Significant contributors to this carbon footprint are the biotech and pharmaceutical industries, directly from the running of these companies (sometimes called scope 1 emissions) and indirectly from purchased energy consumed (scope 2 emissions) and all other emissions indirectly associated with the companies—such as supply chains (scope 3 emissions).2 It is estimated that scope 1, 2 and 3 emissions of biotech and pharmaceutical companies accounted for 260 million tons of carbon dioxide equivalent emissions in 2021, higher than global emissions from the forestry and paper industry.2 There are particular …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140593984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MHRA issues further update on fluoroquinolone safety MHRA 发布氟喹诺酮类药物安全性的进一步更新信息
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2024-04-09 DOI: 10.1136/dtb.2024.000021
BMJ Publishing Group Ltd
### Key learning points The licensed indications for all systemic fluoroquinolones have been updated to restrict their use to situations in which other commonly recommended antibiotics are inappropriate.1 In August and September 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) issued two safety updates on the use of fluoroquinolone antibiotics.1–3 The first update reminded healthcare professionals that systemic fluoroquinolone antibiotics are associated with a risk of …
### 1 2023 年 8 月和 9 月，药品和保健品监管局（MHRA）发布了两份关于氟喹诺酮类抗生素使用的安全性更新。1-3 第一份更新提醒医疗保健专业人员，全身用氟喹诺酮类抗生素与 ...
{"title":"MHRA issues further update on fluoroquinolone safety","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2024.000021","DOIUrl":"https://doi.org/10.1136/dtb.2024.000021","url":null,"abstract":"### Key learning points The licensed indications for all systemic fluoroquinolones have been updated to restrict their use to situations in which other commonly recommended antibiotics are inappropriate.1 In August and September 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) issued two safety updates on the use of fluoroquinolone antibiotics.1–3 The first update reminded healthcare professionals that systemic fluoroquinolone antibiotics are associated with a risk of …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140594014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Donanemab in early symptomatic Alzheimer’s disease 多奈单抗治疗早期症状阿尔茨海默病
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2024-04-05 DOI: 10.1136/dtb.2024.000020
BMJ Publishing Group Ltd
### Key learning points The authors of a phase 3 trial involving people with early Alzheimer’s disease (AD) reported that although donanemab produced a small reduction in clinical progression compared with placebo, it was associated with some serious adverse effects.1 The TRAILBLAZER-ALZ 2 trial was a 76-week, phase 3, randomised, double-blind, placebo-controlled study that recruited participants aged 60–85 years with early symptomatic AD, a Mini-Mental State Examination score of 20–28 and confirmed amyloid and tau pathology assessed by positron emission tomography (PET) scans.1 A total of 1736 …
###学习要点 一项涉及早期阿尔茨海默病（AD）患者的 3 期试验的作者报告说，与安慰剂相比，虽然多那尼单抗能使临床进展略有减少，但它与一些严重的不良反应有关。TRAILBLAZER-ALZ 2 试验是一项为期 76 周的第 3 期随机、双盲、安慰剂对照研究，招募的参与者年龄在 60-85 岁之间，患有早期症状性阿尔茨海默病，迷你精神状态检查评分为 20-28 分，正电子发射断层扫描（PET）评估证实了淀粉样蛋白和 tau 病理学。
{"title":"Donanemab in early symptomatic Alzheimer’s disease","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2024.000020","DOIUrl":"https://doi.org/10.1136/dtb.2024.000020","url":null,"abstract":"### Key learning points The authors of a phase 3 trial involving people with early Alzheimer’s disease (AD) reported that although donanemab produced a small reduction in clinical progression compared with placebo, it was associated with some serious adverse effects.1 The TRAILBLAZER-ALZ 2 trial was a 76-week, phase 3, randomised, double-blind, placebo-controlled study that recruited participants aged 60–85 years with early symptomatic AD, a Mini-Mental State Examination score of 20–28 and confirmed amyloid and tau pathology assessed by positron emission tomography (PET) scans.1 A total of 1736 …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140593996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Do regulatory safety warnings on medicines miss the mark? 药品的监管安全警告是否失误？
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2024-03-25 DOI: 10.1136/dtb.2023.000053
Barbara Mintzes
{"title":"Do regulatory safety warnings on medicines miss the mark?","authors":"Barbara Mintzes","doi":"10.1136/dtb.2023.000053","DOIUrl":"10.1136/dtb.2023.000053","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"50"},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety update: valproate safety and educational materials. 安全性更新：丙戊酸钠的安全性和教育材料。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2024-03-25 DOI: 10.1136/dtb.2024.000013

Overview of: Medicines and Healthcare products Regulatory Agency. Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival and Syonell▼): new safety and educational materials to support regulatory measures in men and women under 55 years of age. Drug Safety Update 2024;17:1.

概述：药品和保健品监管局。丙戊酸钠（Belvo、Convulex、Depakote、Dyzantil、Epilim、Epilim Chrono或Chronosphere、Episenta、Epival和Syonell▼）：支持55岁以下男性和女性监管措施的新安全和教育材料。药物安全更新 2024；17:1。
{"title":"Safety update: valproate safety and educational materials.","authors":"","doi":"10.1136/dtb.2024.000013","DOIUrl":"10.1136/dtb.2024.000013","url":null,"abstract":"<p><p><b>Overview of:</b> Medicines and Healthcare products Regulatory Agency. Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival and Syonell▼): new safety and educational materials to support regulatory measures in men and women under 55 years of age. Drug Safety Update 2024;17:1.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"53"},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139989528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does oseltamivir prevent hospitalisation in people with influenza? 奥司他韦能否预防流感患者住院？
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2024-03-25 DOI: 10.1136/dtb.2024.000016

Overview of: Hanula R, Bortolussi-Courval É, Mendel A, et al. Evaluation of oseltamivir used to prevent hospitalization in outpatients with influenza: a systematic review and meta-analysis. JAMA Internal Medicine 2024;184:18-27.

概述：Hanula R、Bortolussi-Courval É、Mendel A 等人。 用于预防门诊流感患者住院的奥司他韦评估：系统综述和荟萃分析。美国医学会杂志内科学》2024;184:18-27。
{"title":"Does oseltamivir prevent hospitalisation in people with influenza?","authors":"","doi":"10.1136/dtb.2024.000016","DOIUrl":"10.1136/dtb.2024.000016","url":null,"abstract":"<p><p><b>Overview of:</b> Hanula R, Bortolussi-Courval É, Mendel A, et al. Evaluation of oseltamivir used to prevent hospitalization in outpatients with influenza: a systematic review and meta-analysis. JAMA Internal Medicine 2024;184:18-27.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"62 4","pages":"52"},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of topical testosterone on pre-diabetes and diabetes. 局部睾酮对糖尿病前期和糖尿病的影响。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2024-03-25 DOI: 10.1136/dtb.2024.000017

Overview of: Bhasin S, Lincoff AM, Nissen SE, et al. Effect of testosterone on progression from prediabetes to diabetes in men with hypogonadism: a substudy of the TRAVERSE randomized clinical trial. JAMA Intern Med. 2024. doi: 10.1001/jamainternmed.2023.7862. [Epub ahead of print 5 February 2024].

概述：Bhasin S、Lincoff AM、Nissen SE 等：睾酮对男性性腺功能减退症患者从糖尿病前期发展为糖尿病的影响：TRAVERSE 随机临床试验的子研究。JAMA Intern Med.DOI: 10.1001/jamainternmed.2023.7862。[Epub ahead of print 5 February 2024].
{"title":"Effect of topical testosterone on pre-diabetes and diabetes.","authors":"","doi":"10.1136/dtb.2024.000017","DOIUrl":"10.1136/dtb.2024.000017","url":null,"abstract":"<p><p><b>Overview of:</b> Bhasin S, Lincoff AM, Nissen SE, et al. Effect of testosterone on progression from prediabetes to diabetes in men with hypogonadism: a substudy of the TRAVERSE randomized clinical trial. JAMA Intern Med. 2024. doi: 10.1001/jamainternmed.2023.7862. [Epub ahead of print 5 February 2024].</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"62 4","pages":"54"},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of oral penicillin challenge in low-risk penicillin allergy. 在低风险青霉素过敏症中使用口服青霉素挑战。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2024-03-25 DOI: 10.1136/dtb.2024.000015

Overview of: Copaescu AM, Vogrin S, James F, et al. Efficacy of a clinical decision rule to enable direct oral challenge in patients with low-risk penicillin allergy: The PALACE randomized clinical trial. JAMA Intern Med 2023;183:944-52.

概述：Copaescu AM、Vogrin S、James F 等人.低风险青霉素过敏患者直接口服青霉素的临床决策规则疗效：PALACE 随机临床试验》。JAMA Intern Med 2023;183:944-52.
{"title":"Use of oral penicillin challenge in low-risk penicillin allergy.","authors":"","doi":"10.1136/dtb.2024.000015","DOIUrl":"10.1136/dtb.2024.000015","url":null,"abstract":"<p><p><b>Overview of:</b> Copaescu AM, Vogrin S, James F, et al. Efficacy of a clinical decision rule to enable direct oral challenge in patients with low-risk penicillin allergy: The PALACE randomized clinical trial. JAMA Intern Med 2023;183:944-52.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"62 4","pages":"51"},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Slynd: does a drospirenone progestogen-only pill offer an advantage? Slynd：仅使用屈螺酮孕激素的避孕药有优势吗？
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2024-03-25 DOI: 10.1136/dtb.2023.000065
{"title":"Slynd: does a drospirenone progestogen-only pill offer an advantage?","authors":"","doi":"10.1136/dtb.2023.000065","DOIUrl":"10.1136/dtb.2023.000065","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"62 4","pages":"55-59"},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Drug and Therapeutics Bulletin
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1